Ratings by RBC Capital (Daniel Busby)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/25/2023 | Verrica Pharmaceuticals | VRCA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2023 | Verrica Pharmaceuticals | VRCA | Upgrade | Outperform (Sector Perform) |
7.10 (6.65) |
-6.34% | Details | |
| 5/25/2022 | Verrica Pharmaceuticals | VRCA | Downgrade | Sector Perform (Outperform) |
6.30 (6.65) |
5.56% | Details | |
| 9/21/2021 | Verrica Pharmaceuticals | VRCA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2021 | Verrica Pharmaceuticals | VRCA | New Coverage | Outperform (N/A) |
11.45 (6.65) |
-41.92% | Details | |
| 5/14/2021 | MannKind | MNKD | New Coverage | Sector Perform (N/A) |
4.02 (4.18) |
3.98% | Details |
